- I don't follow big pharma names like Novartis $NVS as closely as I do the smaller companies in the BiotechDueDiligence coverage list, but I enjoy the free flowing format at the Goldman Sachs conference and they are a crucial partner for Momenta Pharma (Click here for MNTA research page) on generic Lovenox and Copaxone products, so I thought I would post a few notes.
- See the Past Events page for the webcast link- they are still available as of 7/2/11, but I don't know how much longer that will be the case
- I was hoping to learn about Novartis' perspectives on follow-on biologics (FOBs) aka biosimilars/biogenerics - was covered briefly, and the comments actually slightly increased my perspective on NVS as a potential FOB partner for MNTA
- See my notes below (these are not a complete transcription by any means, just some highlights):